<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Chattem Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/chattem-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Tue, 22 May 2012 18:53:06 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>($SNY) Sanofi-Aventis Expands Presence in U.S. by Aquiring Chattem</title>
		<link>http://www.stockbloghub.com/2009/12/22/sny-sanofi-aventis-expands-presence-in-u-s-by-aquiring-chattem/23452</link>
		<comments>http://www.stockbloghub.com/2009/12/22/sny-sanofi-aventis-expands-presence-in-u-s-by-aquiring-chattem/23452#comments</comments>
		<pubDate>Wed, 23 Dec 2009 00:58:58 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Chattem Inc]]></category>
		<category><![CDATA[CHTT]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23452</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) has decided to acquire U.S.-based Chattem Inc. (CHTT) for $93.50 per share, or approximately $1.9 billion, to create the world’s fifth-largest consumer healthcare company. The offered price represents a 34% premium over Chattem’s Dec. 18th closing price. Currently many pharma players are eyeing the over-the-counter (OTC) segment and consumer brands for portfolio diversification. The transaction, expected to be completed by the first quarter of 2010 is likely to be accretive to Sanofi&#8217;s earnings from the very first year. Although Sanofi is likely to generate around €1.4 billion globally in OTC sales in 2009, the company’s presence in the U.S. has been quite limited. We believe the Chattem acquisition serves the purpose of expanding Sanofi’s presence in this region. The U.S. market is highly lucrative, valued at about $20 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/22/sny-sanofi-aventis-expands-presence-in-u-s-by-aquiring-chattem/23452/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

